A Phase 3 Substudy to Evaluate Executive Function in Adults With Phenylketonuria Who Are Participating in the Phase 3 Study, 165-302
Latest Information Update: 21 Mar 2025
At a glance
- Drugs Pegvaliase (Primary)
- Indications Phenylketonuria
- Focus Therapeutic Use
- Acronyms PRISM303
- Sponsors BioMarin Pharmaceutical
Most Recent Events
- 20 Mar 2025 According to a BioMarin Pharmaceutical media release, positive new data from this study will be presented at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Los Angeles.
- 07 Dec 2017 Status changed from active, no longer recruiting to completed.
- 01 Dec 2015 Planned end date changed from 1 Sep 2016 to 1 Apr 2017, as reported by ClinicalTrials.gov.